BioCentury | Feb 16, 2018
Clinical News

Brickell's sofpironium bromide meets in Phase IIb for hyperhidrosis

...p<0.004) vs. vehicle. Sofpironium bromide was well tolerated with no treatment-related serious adverse events reported. Kaken Pharmaceutical Co. Ltd....
...from Brickell to develop and commercialize the topical soft anticholinergic. Brickell Biotech Inc., Boulder, Colo. Kaken Pharmaceutical Co. Ltd....
BioCentury | Jun 16, 2017
Company News

Numab, Kaken partner to discover multi-specific antibody for inflammatory disease

...Numab Therapeutics AG (Pfaeffikon, Switzerland) and Kaken Pharmaceutical Co. Ltd. (Tokyo:4521) partnered to identify a multi-specific antibody candidate for...
...platform. Under the deal, Kaken will fund Numab’s efforts to identify a multi-specific antibody candidate. Kaken...
...disclose additional details. Numab Therapeutics AG , Pfaeffikon, Switzerland Kaken Pharmaceutical Co. Ltd. (Tokyo:4521), Tokyo, Japan Business: Inflammatory Julian Zhu Kaken Pharmaceutical Co. Ltd. Numab...
BioCentury | Jan 4, 2016
Clinical News

Sofpironium bromide: Phase IIb data

...outcome measure, the Hyperhidrosis Disease Severity Measure Axillary (HDSM-Ax), vs. vehicle. BBI-4000 was well tolerated. Kaken...
...Asian countries from Brickell to develop and commercialize BBI-4000. Brickell Biotech Inc. , Miami, Fla. Kaken Pharmaceutical Co. Ltd....
BioCentury | Jun 16, 2014
Clinical News

Jublia efinaconazole regulatory update

...and South Korea, to the topical triazole antifungal from Kaken (see BioCentury, May 20, 2013). Kaken Pharmaceutical Co. Ltd....
BioCentury | Nov 21, 2013
Targets & Mechanisms

Getting to the root of periodontitis

...DEL1 ; EDIL3 ). 8,9 However, Takuro Yuge, senior manager of R&D strategic planning at Kaken Pharmaceutical Co. Ltd....
...bone deterioration," said Katsumi Nogimori, Kaken's executive corporate officer and deputy chief officer of R&D. Kaken's...
...Haas, M.J. SciBX 6 (45); doi:10.1038/scibx.2013.1281 Published online Nov. 21, 2013 Companies and Institutions Mentioned Kaken Pharmaceutical Co. Ltd....
BioCentury | Nov 11, 2013
Company News

Anacor, Valeant Pharmaceuticals infectious, dermatology news

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken Pharmaceutical Co. Ltd....
BioCentury | Oct 21, 2013
Company News

Anacor, Valeant Pharmaceuticals infectious news

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken Pharmaceutical Co. Ltd....
BioCentury | Oct 7, 2013
Clinical News

Jublia efinaconazole regulatory update

...Valeant has worldwide commercialization rights, excluding Japan, China, Taiwan and South Korea, to efinaconazole from Kaken...
...hear from the judge in the case "in a few weeks" (see BioCentury, May 20). Kaken Pharmaceutical Co. Ltd....
BioCentury | Jun 3, 2013
Clinical News

Efinaconazole regulatory update

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken...
...fiduciary duty, intentional interference with prospective business advantage and unfair competition (see BioCentury, May 20). Kaken Pharmaceutical Co. Ltd....
BioCentury | May 20, 2013
Company News

Anacor, Valeant Pharmaceuticals sales and marketing update

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 36
BioCentury | Feb 16, 2018
Clinical News

Brickell's sofpironium bromide meets in Phase IIb for hyperhidrosis

...p<0.004) vs. vehicle. Sofpironium bromide was well tolerated with no treatment-related serious adverse events reported. Kaken Pharmaceutical Co. Ltd....
...from Brickell to develop and commercialize the topical soft anticholinergic. Brickell Biotech Inc., Boulder, Colo. Kaken Pharmaceutical Co. Ltd....
BioCentury | Jun 16, 2017
Company News

Numab, Kaken partner to discover multi-specific antibody for inflammatory disease

...Numab Therapeutics AG (Pfaeffikon, Switzerland) and Kaken Pharmaceutical Co. Ltd. (Tokyo:4521) partnered to identify a multi-specific antibody candidate for...
...platform. Under the deal, Kaken will fund Numab’s efforts to identify a multi-specific antibody candidate. Kaken...
...disclose additional details. Numab Therapeutics AG , Pfaeffikon, Switzerland Kaken Pharmaceutical Co. Ltd. (Tokyo:4521), Tokyo, Japan Business: Inflammatory Julian Zhu Kaken Pharmaceutical Co. Ltd. Numab...
BioCentury | Jan 4, 2016
Clinical News

Sofpironium bromide: Phase IIb data

...outcome measure, the Hyperhidrosis Disease Severity Measure Axillary (HDSM-Ax), vs. vehicle. BBI-4000 was well tolerated. Kaken...
...Asian countries from Brickell to develop and commercialize BBI-4000. Brickell Biotech Inc. , Miami, Fla. Kaken Pharmaceutical Co. Ltd....
BioCentury | Jun 16, 2014
Clinical News

Jublia efinaconazole regulatory update

...and South Korea, to the topical triazole antifungal from Kaken (see BioCentury, May 20, 2013). Kaken Pharmaceutical Co. Ltd....
BioCentury | Nov 21, 2013
Targets & Mechanisms

Getting to the root of periodontitis

...DEL1 ; EDIL3 ). 8,9 However, Takuro Yuge, senior manager of R&D strategic planning at Kaken Pharmaceutical Co. Ltd....
...bone deterioration," said Katsumi Nogimori, Kaken's executive corporate officer and deputy chief officer of R&D. Kaken's...
...Haas, M.J. SciBX 6 (45); doi:10.1038/scibx.2013.1281 Published online Nov. 21, 2013 Companies and Institutions Mentioned Kaken Pharmaceutical Co. Ltd....
BioCentury | Nov 11, 2013
Company News

Anacor, Valeant Pharmaceuticals infectious, dermatology news

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken Pharmaceutical Co. Ltd....
BioCentury | Oct 21, 2013
Company News

Anacor, Valeant Pharmaceuticals infectious news

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken Pharmaceutical Co. Ltd....
BioCentury | Oct 7, 2013
Clinical News

Jublia efinaconazole regulatory update

...Valeant has worldwide commercialization rights, excluding Japan, China, Taiwan and South Korea, to efinaconazole from Kaken...
...hear from the judge in the case "in a few weeks" (see BioCentury, May 20). Kaken Pharmaceutical Co. Ltd....
BioCentury | Jun 3, 2013
Clinical News

Efinaconazole regulatory update

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken...
...fiduciary duty, intentional interference with prospective business advantage and unfair competition (see BioCentury, May 20). Kaken Pharmaceutical Co. Ltd....
BioCentury | May 20, 2013
Company News

Anacor, Valeant Pharmaceuticals sales and marketing update

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 36